Company news

MIRA Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

October 27, 2024

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

October 20, 2024

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

September 26, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

September 18, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

September 17, 2024

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

September 10, 2024

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain with Oral Ketamir-2 in Breakthrough Study

August 27, 2024

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

August 25, 2024

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

August 18, 2024

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite, Nor-Ketamir a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

August 13, 2024

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

August 11, 2024

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

July 28, 2024

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

July 26, 2024

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action

July 24, 2024

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

July 21, 2024

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

July 14, 2024

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

June 23, 2024

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

June 9, 2024

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

May 28, 2024

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

May 19, 2024

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

April 1, 2024

MIRA Pharmaceuticals Provides Corporate Update

February 4, 2024

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

December 3, 2023

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

November 28, 2023

MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11: 30 a.m. Eastern Time

November 20, 2023

MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

November 20, 2023

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

November 19, 2023

MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot

September 17, 2023

MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1: 00 p.m. Eastern Time

August 28, 2023

← Newer news releases

Decks